Julien Payen, Lattice Medical - Implants for Soft Tissue Regeneration | LSI USA '24

Julien Payen  0:04  
Lattice Medical is a clinical stage company, specialized in innovative solution for reconstructive surgery. Howlett product is in the breast cancer. It's the first cancer in the world for a woman that one woman on eight and we have for the cancer treatment takes 150,000 mastectomy every year in Europe and US and the reconstruction cost is high. It's $67,000 for reconstruction for Reconstruction and overhead costs. We have different techniques to reconstruct a breast breast implant is the gold standard, you will use silicone implant. It's the long term material wave leading complication in the long term and you need to replace it every 10 years. And on the other side, you have autologous surgeries such as flap or lipofilling, iterative or highly invasive leading to back pain and loss of strength. Women are looking for a natural way to reconstruct a breast less invasive and long lasting. So that's why we have introduced Matisse. Matisse is a tissue engineering chamber. Hello wing, the regeneration of autologous adipose tissue restoring the breast volume. Matisse is a degradable implant leading to a natural feeling after reconstruction. And it's a one hour surgery instead of four rails installed at flap procedures. Here's a video of the operative technique. On this example, this woman had a full mastectomy on the left breast. And for the reconstruction the entryway is in the sub mammary fold. The surgeon will have us fat flap just below the breast between the seventh and eighth intercostal area. It's a fat flap of fat at age 100 cc of fat, and the fat will be inserted into Mattis. Mattis is in two parts. The bottom layer is called the scaffold and we fix the tissue with six stitches. And then we close with the chamber the chamber can have different size and shape thanks to 3d printing. It's introduced in a predictable planar we fix it on the chest and we close the wound. And during three to six months, the tissue inside will regenerates feeling it's slowly the inner part of the implant in the in the meantime, it's resolving after all the patient get back in your breast with a horn tissue and Wi Fi without any device in the body. We have incorporated Lattice Medical seven years ago with myself to medical doctors and plastic surgeon in from Lille hospital in the north of France. We are 25 in the company and surrounded with key opinion leaders in the plastic surgery area. And we have also retained experts in the reimbursement and regulatory. We have already raised 20 million in two round seed and series A and we have operations in US and France. We succeeded in the past on all preclinical data. Here is a summary of our large animal study on pigs. We use the MRI to check the volume regeneration. So in this example, you see the initial tissue on the left. And in 90 days in this example the tissue regenerating filling the inner parts. And on this curve, you have the kinetics it takes almost six months to reach a maximum volume. And after a two year survey after the full resolution of the device, the tissue is stable and it's highly reproducible. Thanks to these results we have been granted to start last year first in human study. It's called the tight study for a woman eligible to breast reconstruction after a total mastectomy. It's a safety and performance study involving 50 patients of three years follow up in France and Spain. And we work with the best European European leaders of that in Paris least has BU and Barcelona. Here's a first perspective of our first results on a one year follow up. We have one hour of surgery instead of four installed flat procedures, low pain and one closure in 40 days. This example it's a 63 years old woman she had a full mastectomy on the right breast so this is before the surgery. We use the MRI seven days after to make the initial statement of the size of tissue. Three months after we show an increase in tissue size, a double of size in only three months. And after one year. The implant has no sensation of implant afters. Next month, and it disappeared from the MRI confirming the resolution and the patient gets a full reconstruction with a whole tissue at the end and without any device in the body. How predict franchise is protected by a strong IP for a different pattern family with 13 patents and a total granted in US Europe and Brazil, two key geographic areas and a coverage until 2014. And we have also an innovative way to produce the device we have done how on printing farm from the raw material extrusion on the left 3d printing. So we make the raw material extrusion to the filament, the filament is loaded behind the 3d printers, and each printer are able to produce each implant. From our different trends. We have a project also in patient specific and it's ISO certified in cleanroom, etc, etc. Thanks to IP and platform, we have different products in development, Matisse for the breast reconstruction and breast aesthetics Voda for the deep wound damage and reconstruction and new at least for the tissue reinforcements. The total addressable market for Matisse is 3.5 billion divided into sub market breast reconstruction and breast augmentation. Here are three key geographic areas us first in value and volume Europe and Brazil and the breast implant market as industry leaders. It's a growing market with a high request on alternative solution to silicon. Our business and review model is based on the first reimbursement strategy in breast reconstruction, the reduction of surgery costs. First of all, the resumption of device means less complication and a long time and no replacement of implant like silicone. It's a free hours reduction surgery time instead of flap standard surgery and waiting for the reimbursement. We can also have a cash pay revenue in the cosmetic application of Mattis. We have a premium product strategy pricing, reaching high marking and we are also looking for licensing opportunity in the landscape to be connected with industry leaders to start the sales to reach a 38 million revenue by 2030. So finally, what's our development and request here? Thanks to the series A we have launched the premarket clinical investigation in Europe the tight study. In the meantime, we hind the presser meeting process and clinical design in us. We want to raise a series B of 45 million in order to launch a PMA clinical investigation in US involving 325 patients in all breast reconstruction indication included in Indian Medical academic criteria to get the reimbursement in parallel we will have the CE mark in 2026 recruiting the size and starting the sales in Europe and reimbursements 30 in European soil for the breast reconstruction application and then a budget to increase our production capacity on our 3d printing factory. So to summarize, we are looking for 45 million Series B for a PMA start sales in Europe licensing partnership and industrial scale up and try to improve the quality of life all lumen in the breast cancer journey. Thank you